Glytec, a provider of an AI-powered technology platform for diabetes and related conditions, closed a $36 million growth investment led by Savitr Capital and Hayfin Capital Management. This funding will fuel the continued expansion of Glytec’s platform, including its flagship Glucommander SaaS solution, accelerate the development of innovative new technologies to address the growing global health crisis of diabetes and related co-morbidities and support the continued response to upcoming CMS quality measures that will hold health systems accountable for inpatient glycemic control.
“This investment is a pivotal moment for Glytec, validating our vision of a future where deep data-driven insights empower clinicians to deliver highly individualized and proactive care for diabetes and metabolic conditions,” Patrick Cua, CEO of Glytec, said. “Savitr Capital and Hayfin Capital share our belief in the transformative power of technology to improve patient outcomes and alleviate the burden of complex chronic diseases. This capital will enable us to expand our R&D initiatives, scale our platform and continue to attract top-tier talent as we revolutionize metabolic healthcare.”
“Glytec stands at the intersection of cutting-edge AI and critical healthcare need,” Andrew Midler, managing member of Savitr Capital, said. “Their proven track record with Glucommander and their broader vision for combining digital technology and AI to help hospitals improve patient care, make Glytec a compelling investment.”
“We are impressed by Glytec’s robust technology, clinical efficacy, and commitment to improving patient lives,” Andrew Merrill, managing director of Hayfin Capital Management, said. “Their platform approach to metabolic health, particularly their success in inpatient glucose management, demonstrates a profound understanding of complex clinical challenges and a scalable solution to address them. We are excited to support Glytec’s continued growth and impact.”
